SCHEMBL27161993

SCHEMBL27161993

O=S(=O)(c1ccc(N2CCOCC2)nc1)N1CCCC2(CCN(Cc3ccccc3)CC2)C1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 9/20 0.58
▸ CYP2D6 P10635 9/20 0.58
▸ TSHR P16473 8/20 0.58
▸ CYP1A2 P05177 6/20 0.58
▸ USP2 O75604 6/20 0.58
▸ ALDH1A1 P00352 5/20 0.54
▸ SMN1; SMN2 Q16637 5/20 0.53
▸ LMNA P02545 1/20 0.51
▸ KDM4E B2RXH2 2/20 0.50
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ CYP2C9 P11712 4/20 0.48
▸ CYP2C19 P33261 4/20 0.48
▸ GAA P10253 3/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050081 1.00 CYP3A4 (0.58) CYP3A4CYP2D6TSHRCYP1A2USP2
SCHEMBL31097543 0.95 ALDH1A1 (0.57) CYP3A4CYP2D6TSHRCYP1A2USP2
SCHEMBL27162633 0.95 ALDH1A1 (0.57) CYP3A4CYP2D6TSHRCYP1A2USP2
SCHEMBL27162872 0.92 ALDH1A1 (0.53) CYP3A4CYP2D6TSHRCYP1A2USP2
SCHEMBL30050718 0.92 ALDH1A1 (0.53) CYP3A4CYP2D6TSHRCYP1A2USP2
SCHEMBL27162537 0.90 ALDH1A1 (0.60) CYP3A4CYP2D6TSHRCYP1A2USP2
SCHEMBL30050728 0.90 ALDH1A1 (0.60) CYP3A4CYP2D6TSHRCYP1A2USP2
SCHEMBL30049486 0.90 ALDH1A1 (0.63) CYP3A4CYP2D6TSHRUSP2ALDH1A1
SCHEMBL27162132 0.90 ALDH1A1 (0.63) CYP3A4CYP2D6TSHRUSP2ALDH1A1
SCHEMBL30049372 0.89 CYP3A4 (0.58) CYP3A4CYP2D6TSHRCYP1A2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US claimed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 CYP3A4 497/4885CYP2D6 514/4885TSHR 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback